Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

NCT04257162 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT04257162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04257162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 13, 2019
Completion date
May 31, 2028
Enrollment
180 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer